Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Total Current Assets
All assets expected to be converted to cash or used up within one year.
Alumis Inc. Common StockNASDAQ: ALMS
Total Current Assets · Q2 FY2026 · quarter ended Jun 2026
Total current assets broadly unchanged from a year ago
Total current assets stood at $514.08M at the end of Q2 FY2026, down 0.7% from a year earlier and down 3.4% from the prior quarter. Over 3 fiscal years it compounded at +45.9% a year.
Context
- Total current assets amounted to 91.7% of total assets at the end of Q2 FY2026, up 7.0 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -0.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 318.23M USD
- Year-over-year change
- +3.9%
- 3-year CAGR
- +45.9%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 318.23M | +3.9% |
| FY2024 | 2024-12-31 | 306.19M | +473.8% |
| FY2023 | 2023-12-31 | 53.36M | -48.0% |
| FY2022 | 2022-12-31 | 102.56M | — |
Total Current Assets vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -0.7% is the 4th highest of 9, against a peer median of -20.7%.
- Total current assets amounts to 91.7% of total assets for ALMS, versus a peer median of 83.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $514.08M USD | -0.7% | +45.9% | 91.7% |
| Mar 2026 | $316.11M USD | -12.9% | -7.8% | 95.9% | |
| Mar 2026 | $234.03M USD | +59.7% | +27.5% | 46.4% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €133.01M EUR | — | — | 80.3% |
| Mar 2026 | $110.23M USD | +1.3% | -13.2% | 55.5% | |
| Mar 2026 | $88.83M USD | -30.0% | +85.8% | 88.9% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $88.74M USD | -47.8% | +2.5% | 83.8% |
| Mar 2026 | $66.27M USD | -28.5% | -26.5% | 99.7% | |
| Mar 2026 | €47.45M EUR | -44.6% | -18.0% | 96.9% | |
| Dec 2025 | $8.55M USD | +13.9% | -29.4% | 74.4% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -20.7% | -10.5% | 83.8% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.